Axitinib Patent Expiration
Axitinib is Used for the treatment of advanced renal cell carcinoma, typically in combination with other medications like avelumab or pembrolizumab. It was first introduced by Pf Prism Cv
Axitinib Patents
Given below is the list of patents protecting Axitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inlyta |
US10869924 (Pediatric) | PD-L1 antagonist combination treatments | Jul 12, 2037 | Pf Prism Cv |
| Inlyta | US10869924 | PD-L1 antagonist combination treatments | Jan 12, 2037 | Pf Prism Cv |
| Inlyta |
US10570202 (Pediatric) | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer | Aug 03, 2035 | Pf Prism Cv |
| Inlyta |
US12534530 (Pediatric) | Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer | Aug 03, 2035 | Pf Prism Cv |
| Inlyta | US10570202 | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer | Feb 03, 2035 | Pf Prism Cv |
| Inlyta | US12534530 | Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer | Feb 03, 2035 | Pf Prism Cv |
| Inlyta |
US8791140 (Pediatric) | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals | Jun 14, 2031 | Pf Prism Cv |
| Inlyta | US8791140 | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals | Dec 14, 2030 | Pf Prism Cv |
| Inlyta |
US6534524 (Pediatric) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Oct 29, 2025
(Expired) | Pf Prism Cv |
| Inlyta | US6534524 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr 29, 2025
(Expired) | Pf Prism Cv |
| Inlyta | US7141581 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Jun 30, 2020
(Expired) | Pf Prism Cv |
Axitinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Axitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
